LPL Financial Holdings Inc. (LPLA) is a Great Momentum Stock: Should You Buy? — Positive
LPLA Zacks Investment Research — February 12, 2025Does LPL Financial Holdings Inc. (LPLA) have what it takes to be a top stock pick for momentum investors? Let's find out.
CyberArk (CYBR) is a Great Momentum Stock: Should You Buy? — Positive
CYBR Zacks Investment Research — February 12, 2025Does CyberArk (CYBR) have what it takes to be a top stock pick for momentum investors? Let's find out.
CyberArk (CYBR) Upgraded to Buy: Here's What You Should Know — Positive
CYBR Zacks Investment Research — February 12, 2025CyberArk (CYBR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Are You Looking for a Top Momentum Pick? Why Robinhood Markets, Inc. (HOOD) is a Great Choice — Positive
HOOD Zacks Investment Research — February 12, 2025Does Robinhood Markets, Inc. (HOOD) have what it takes to be a top stock pick for momentum investors? Let's find out.
Adaptive Biotechnologies (ADPT) Moves to Buy: Rationale Behind the Upgrade — Positive
ADPT Zacks Investment Research — February 12, 2025Adaptive Biotechnologies (ADPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Are You Looking for a Top Momentum Pick? Why Expedia (EXPE) is a Great Choice — Positive
EXPE Zacks Investment Research — February 12, 2025Does Expedia (EXPE) have what it takes to be a top stock pick for momentum investors? Let's find out.
Post Holdings (POST) Upgraded to Buy: Here's What You Should Know — Positive
POST Zacks Investment Research — February 12, 2025Post Holdings (POST) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Castle Biosciences (CSTL) Upgraded to Buy: Here's Why — Positive
CSTL Zacks Investment Research — February 12, 2025Castle Biosciences (CSTL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Criteo S.A. (CRTO) is a Great Momentum Stock: Should You Buy? — Positive
CRTO Zacks Investment Research — February 12, 2025Does Criteo S.A. (CRTO) have what it takes to be a top stock pick for momentum investors?
Doximity (DOCS) is a Great Momentum Stock: Should You Buy? — Positive
DOCS Zacks Investment Research — February 12, 2025Does Doximity (DOCS) have what it takes to be a top stock pick for momentum investors? Let's find out.
CompoSecure (CMPO) Upgraded to Buy: Here's What You Should Know — Positive
CMPO Zacks Investment Research — February 12, 2025CompoSecure (CMPO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
BRICS banks bleeding gold bars: China and Russia face runaway gold demand — Negative
AAAU BAR DBP DGL GLD GLDM IAU OUNZ SGOL UGL Kitco — February 12, 2025Ernest Hoffman is a Crypto and Market Reporter for Kitco News. He has over 15 years of experience as a writer, editor, broadcaster and producer for media, educational and cultural organizations.
ESTC SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Elastic N.V. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! — Neutral
ESTC Accesswire — February 12, 2025NEW YORK, NY / ACCESS Newswire / February 12, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Elastic N.V. ("Elastic" or "the Company") (NYSE:ESTC) and certain of its officers.
Applies for $58 Million with the Department of Defense Office of Strategic Capital Applies for $58 Million with the Department of Defense Office of Strategic Capital
MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting — Neutral
INKT GlobeNewsWire — February 12, 2025NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that it has been selected for an oral presentation at the upcoming American Association for Cancer Research (AACR) IO Annual Meeting that will take place on February 23-26 in Los Angeles, California. The oral presentation will highlight interim data from the company's ongoing Phase 2 study testing AgenT-797 in combination with Agenus' lead therapeutic combination, botensilimab and balstilimab …
Agenus' BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting — Neutral
AGEN Business Wire — February 12, 2025LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced that BOT/BAL will be featured in two presentations at the upcoming American Association for Cancer Research (AACR) IO Annual Meeting that will take place on February 23-26 in Los Angeles, California. An oral presentation will highlight interim data from the ongoing Phase 2 study of botensilimab and balstilimab (BOT/BAL) in combination with MiNK Therapeutics' iNKT cell therapy, AgenT-797,.
Churchill Downs Incorporated Opens Owensboro Racing & Gaming in Western Kentucky — Neutral
CHDN GlobeNewsWire — February 12, 2025$100 Million Investment Provides World-Class Entertainment While Supporting Purse Funding for Ellis Park $100 Million Investment Provides World-Class Entertainment While Supporting Purse Funding for Ellis Park
Regis Corporation (RGS) Q2 2025 Earnings Call Transcript — Neutral
RGS Seeking Alpha — February 12, 2025Regis Corporation (NASDAQ:RGS ) Q2 2025 Earnings Conference Call February 12, 2025 8:30 AM ET Company Participants Kersten Zupfer - EVP and Chief Financial Officer Matthew Doctor - President and Chief Executive Officer Conference Call Participants Operator Good morning, and thank you for joining the Regis Second Quarter 2025 Earnings Conference Call. I am your host, Kersten Zupfer, Executive Vice President and Chief Financial Officer.
Shareholders that lost money on Neumora Therapeutics, Inc.(NMRA) should contact The Gross Law Firm about pending Class Action - NMRA — Neutral
NMRA GlobeNewsWire — February 12, 2025NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Neumora Therapeutics, Inc. (NASDAQ: NMRA).
Investors who lost money on Crocs, Inc. (CROX) should contact The Gross Law Firm about pending Class Action - CROX — Neutral
CROX GlobeNewsWire — February 12, 2025NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Crocs, Inc. (NASDAQ: CROX).
